![Gareth Edward King](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gareth Edward King
Directeur/Membre du Conseil chez
Proveca Ltd.
Profil
Dr. Gareth E.
King is Life Science Partner at Catapult Venture Managers Ltd.
Prior to joining Catapult Venture, Dr. King was Chief Executive Officer at Critical Pharmaceuticals Ltd, Project Leader at AstraZeneca Pharmaceuticals LP, Researcher at Harvard Medical School, a Principal at Cyprotex Plc and Incyte Pharmaceuticals, Inc.
Dr. King received his BSc in Microbiology from The University of Sheffield and a PhD in Molecular Genetics from The University of Edinburgh.
Postes actifs de Gareth Edward King
| Sociétés | Poste | Début |
|---|---|---|
Catapult Ultimate Holdings Ltd.
 Catapult Ultimate Holdings Ltd. Investment ManagersFinance Catapult Ultimate Holdings invests in private companies located in the United Kingdom. The firm focuses healthcare & pharmaceuticals, luxury consumer brands, manufacturing and software. It participates in seed, early and later stage capital requirements. | Private Equity Investor | - |
Proveca Ltd.
 Proveca Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for children and adults | Directeur/Membre du Conseil | - |
Anciens postes connus de Gareth Edward King
| Sociétés | Poste | Fin |
|---|---|---|
| CYPROTEX PLC | Corporate Officer/Principal | - |
Incyte Pharmaceuticals, Inc.
 Incyte Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Corporate Officer/Principal | - |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
AstraZeneca Pharmaceuticals LP
 AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceuticals | Corporate Officer/Principal | - |
Critical Pharmaceuticals Ltd.
 Critical Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company with interest in developing and producing biological drug products | Directeur Général | - |
Formation de Gareth Edward King
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
13
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Cyprotex Ltd.
 Cyprotex Ltd. Miscellaneous Commercial ServicesCommercial Services Provides pharmaceutical research and development services | Commercial Services |
Incyte Pharmaceuticals, Inc.
Incyte Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
The University of Edinburgh
 The University of Edinburgh Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Sheffield
 The University of Sheffield Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceuticals | Health Technology |
Critical Pharmaceuticals Ltd.
Critical Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company with interest in developing and producing biological drug products | Health Technology |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Proveca Ltd.
Proveca Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for children and adults | Health Technology |
Catapult Ultimate Holdings Ltd.
Catapult Ultimate Holdings Ltd. Investment ManagersFinance Catapult Ultimate Holdings invests in private companies located in the United Kingdom. The firm focuses healthcare & pharmaceuticals, luxury consumer brands, manufacturing and software. It participates in seed, early and later stage capital requirements. | Finance |
